940 results on '"Tewari, Krishnansu S."'
Search Results
202. Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy
203. Implementation of human papillomavirus video education for women participating in mass cervical cancer screening in Tanzania
204. Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?
205. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer
206. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).
207. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
208. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
209. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
210. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study
211. Tumors of the Cervix
212. Cancer in Pregnancy
213. Invasive Cervical Cancer
214. Contributors
215. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.
216. Current and Emerging Immunotherapies for Recurrent Cervical Cancer.
217. Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18
218. PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel
219. Gynecologic cancer in pregnancy
220. Robotic surgery for gynecologic cancers: indications, techniques and controversies
221. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma
222. Philip John DiSaia, MD: Available Light & The Origin of Storms
223. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
224. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer
225. Reply to Farolfi et al and Haines et al
226. Cancer in Pregnancy
227. Contributors
228. Invasive Cervical Cancer
229. Minimally Invasive Surgery for Early-Stage Cervical Carcinoma: Interpreting the Laparoscopic Approach to Cervical Cancer Trial Results
230. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
231. The Influence of Conservative Surgical Practices for Malignant Ovarian Germ Cell Tumors
232. Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
233. Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma.
234. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
235. Therapeutic vaccination using HPV 16 E7 to eradicate CIN3.
236. RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
237. 15 - Cancer in Pregnancy
238. 3 - Invasive Cervical Cancer
239. Survival With Cemiplimab in Recurrent Cervical Cancer.
240. Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma
241. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
242. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
243. Immune Checkpoint Blockade in PD-L1–Positive Platinum-Refractory Cervical Carcinoma
244. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
245. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
246. Therapeutic vaccination using HPV 16 E7 to eradicate CIN3
247. Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
248. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study
249. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study
250. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.